Catalyst Biosciences initiated at Oppenheimer

Catalyst Biosciences initiated with Outperform at Oppenheimer. Oppenheimer analyst Kevin DeGeeter initiated Catalyst Biosciences with an Outperform rating and a price target of $24. The analyst notes that the company offers a “unique approach” in hemophilia treatment, asking key questions about the “best method to transition inhibitor patients from products designed to treat bleeding to prophylaxis for preventing bleeds” and the optimal treatment of “pediatric hemophilia B patients that are not candidates for subcutaneous non-factor replacement therapies or gene therapy”. DeGeeter contends that investors are under-appreciating Catalyst Biosciences’ Factor VIIa program and anticipates the investment story for the stock to solidify this year.
https://thefly.com/landingPageNews.php?id=2843503